 Strides Pharma Science Ltd consolidated Q2FY26 net profit climbs to Rs. 127.53 crores
Strides Pharma Science Ltd consolidated Q2FY26 net profit climbs to Rs. 127.53 crores ASI Industries Ltd Q2FY26 profit at Rs. 81.30 lakhs
ASI Industries Ltd Q2FY26 profit at Rs. 81.30 lakhs Jubilant Pharmova Ltd consolidated Q2FY26 net profit rises to Rs. 120.3 crores
Jubilant Pharmova Ltd consolidated Q2FY26 net profit rises to Rs. 120.3 crores Bharat Electronics Ltd Q2 FY2025-26 consolidated profit at Rs. 1287.77 crores
Bharat Electronics Ltd Q2 FY2025-26 consolidated profit at Rs. 1287.77 crores ACC Ltd consolidated Q2 FY2026 PAT zooms to Rs. 1119.23 crores
ACC Ltd consolidated Q2 FY2026 PAT zooms to Rs. 1119.23 crores 
              Sterlite's Q1FY11 consol. EBITDA grew 35% YoY to Rs15bn mainly on account of higher LME zinc price (up 36% YoY), increased copper TcRc & by-product revenue. Adj. PAT increased at a subdued 29% to Rs8.7bn due to share of ~Rs785mn in loss in associate VAL. As on June 2010, Sterlite has consolidated cash and equivalents of Rs249bn.
OUTLOOK
Sterlite Industries is uniquely placed on account of diversified asset portfolio, highly cost competitive operations, robust organic growth and strong balance sheet. We believe that commencement of 2,400MW at Sterlite Energy would provide stability to earnings.
VALUATIONS AND RECOMMENDATION
At CMP of Rs174, the stock is trading at 6.8x FY10 EV/EBITDA. The stock is currently under review. 'NOT RATED'.